OBS Medical

Abingdon, UK -  18^th March 2010.  OBS Medical is delighted to announce that Depomed Inc have selected mPRO^tm to provide a Patient Recorded Outcome system for their Breeze 3 study.  The decision by Depomed starts a new relationship with OBS Medical and and further develops an exciting initiative to use mobile phones to record patient outcomes.  The award marks a major milestone for OBS Medical in extending the use of mPRO^tm from phase 2 studies into a large scale, phase 3 clinical trial.

The Breeze 3 study is a phase 3 trial of Sereda^tm, an investigational formulation of Gabapentin for the treatment of Hot Flashes in post menopausal women

mPRO^tm provides a unique yet practical method of gathering electronic patient reported data on a mobile phone.  mPRO^tm has been used in a number of clinical studiers to date involving several hundred subjects. mPRO^tm enables researchers and their staff to review and analyse real time information.  It can also be a quick and effective communication tool with trial subjects.

Fully customisable diaries, using adaptive branch logic are down loaded to mobile phones.  Subjects answer diary questions via their mobile phone and the data is automatically sent wirelessly to a secure server.  Researchers and staff can instantly access subjects’ real-time information and begin to quantify and qualify study trends and analysis.

“mPRO^tm offers significant advantages over traditional methods of collecting information from trial subjects” says Alex Orsinski, Director, Business Development “The setup and roll out of questionnaires to subjects is fast, meaning that studies can commence more quickly and finish sooner.  Mobile phones provide a familiar and easy to use interface which boosts compliance rates, and the system offers real time information as a study progress, which means that study coordinators and researches can quickly see what is happening through the trial”

For more information please contact OBS Medical, sales@obsmedical.com, UK +44 (0)1235 432050: US +1 919 969 9839.

Note to editors:

1. Depomed Inc is a specialty pharmaceutical company focused on enhancing pharmaceutical products. Since its founding in August 1995, the company has advanced two products to market and has developed a pipeline with late-stage product opportunities intended to address common medical conditions affecting large patient populations.
2. OBS Medical is an organisation focussed on improving patient outcomes through real time monitoring.  The company’s product offerings cover the whole range of health care environments from acute hospital wards to the home with benefits including reduced hospital admissions and length of stay, improved management of Long Term Conditions and improved quality of life for patients.

Congratulations to Trudy Kuipers–de Groot of Astellas Pharma.
An ipod touch will be with you shortly…

Commiserations to all those who entered but did not win.

t+ Clinical’s mPRO (mobile patient reported outcomes) solution is short-listed for the Good Clinical Practice Journal Awards 2008.

The mPRO solution runs over the world’s largest data infrastructure, operates on mobile phones in every geography and delivers familiar, high compliance technology to study subjects worldwide. Using a unique yet practical method of gathering electronic patient recorded data through mobile phones, t+ Clinical are able to offer fast rollout within days of a finalised study, combined with real time analysis of primary outcomes.

The annual Good Clinical Practice Journal Awards are designed to recognise the remarkable achievements of individuals and organisations working in the clinical trial industry. t+ Clinical are short-listed under ‘Best technological development in clinical trials’ and in this category judges are looking for the product that represents the best advance in supporting clinical trial management.

“Outstanding. Exemplary. Impressive.” These are just some of the comments received from the judges about this years GCPj entries. Proving once again that the clinical trials sector is buzzing with innovation and a continued commitment to improving trial processes.

About t+ Clinical: established in 2007 as a subsidiary to t+ Medical Holdings, to offer data capture solutions to pharmaceutical customers for late stage clinical trials. The vision of t+ Clinical is to enable the drug discovery process to move as quickly and accurately as possible through mobile phone based, late stage clinical trials. By ensuring that every stage of data collection and analysis is as efficient as possible, high standard results are delivered in the shortest time.

For further information please e mail info@tplusclinical.com or call  +44 (0) 1235 432050

www.tplusclinical.com

www.gcpjawards.com

t+ Clinical launch a mobile phone based mPRO (mobile patient recorded outcomes) solution at the 44th annual meeting of the Drug Information Association in Boston USA, 22nd to 26th June 2008.

t+ Clinical is an electronic patient reported outcome solution that runs over the worlds largest data infrastructure. Using a unique mobile phone based data capture solution, t+ Clinical are able to offer fast rollout within days of a finalised study, combined with real time analysis of primary outcomes.

The DIA was the first opportunity to demonstrate the technology to potential customers, and t+ Clinical are looking forwards to introducing their unique product into the world of clinical trials.

President and CEO of t+ Clinical Tim Clover said “By effectively using a disposable cell phone handset and an automated custom questionnaire engine we will deliver substantial benefits in both speed of rollout and real-time technical performance to CRO’s and drug discovery companies worldwide. Using such familiar technology we have been able to generate almost – subject compliance, offering further potential savings in subject populations and study duration.”

About t+ Clinical: established in 2007 as a subsidiary to t+ Medical Holdings, to offer data capture solutions to pharmaceutical customers for late stage clinical trials. The vision of t+ Clinical is to enable the drug discovery process to move as quickly and accurately as possible through mobile phone based, late stage clinical trials. By ensuring that every stage of data collection and analysis is as efficient as possible, high standard results are delivered in the shortest time.

For further information please e mail info@tplusclinical.com or call
UK +44 (0) 1235 432056
USA  910.442.3040

www.tplusclinical.com